The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.

The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.

Combined targeting of the MAPK and PI3K signalling pathways in cancer may be necessary for optimal therapeutic activity. To support clinical studies of combination therapy, 3'-deoxy-3'-[(18)F]-fluorothymidine ([(18)F]-FLT) uptake measured by Positron Emission Tomography (PET) was evaluated...

Full description

Bibliographic Details
Main Authors: Emma J Haagensen, Huw D Thomas, Ian Wilson, Suzannah J Harnor, Sara L Payne, Tommy Rennison, Kate M Smith, Ross J Maxwell, David R Newell
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3858267?pdf=render

Internet

http://europepmc.org/articles/PMC3858267?pdf=render

Similar Items